BACKGROUND AND PURPOSE: Peroxisome proliferator-activated receptor (PPAR) agonists exert anti-albuminuric effects. However, the nephroprotective effects of these drugs remain to be fully understood. We have investigated whether gemfibrozil, GW0742 and pioglitazone protect human podocytes against nutrient deprivation (ND)-induced cell death and the role of mitochondrial biogenesis as a cytoprotective process. EXPERIMENTAL APPROACH: Immortalized human podocytes were pre-treated with the PPAR agonists and exposed to ND (5 h) under normoxia, hypoxia or in the presence of pyruvate. Cell death was measured at the end of the ND and of the recovery phase (24 h). Mitochondrial mass, cytochrome c oxidase (COX) subunits 1 and 4 were measured as markers of mitochondrial cell content, while membrane potential as an index of mitochondrial function. PGC-1α, NRF1 and Tfam expression was studied, as crucial regulators of mitochondrial biogenesis. KEY RESULTS: Cell pre-treatment with gemfibrozil, GW0742, or pioglitazone significantly decreased the ND-induced cell loss, necrosis and apoptosis. These effects were attenuated by hypoxia and potentiated by pyruvate. Pre-treatment with these drugs significantly increased mitochondrial cell content, while it did not affect mitochondrial function. In all these experiments pioglitazone exerted significantly larger effects than gemfibrozil or GW0742. CONCLUSIONS AND IMPLICATIONS: Gemfibrozil, GW0742 and pioglitazone may exert direct protective effects on human podocytes. Mitochondrial biogenesis is a cell response to the PPAR agonists related to their cytoprotective activity. These results provide a mechanistic support to the clinical evidence indicating PPAR agonists as disease-modifying agents for glomerular diseases.
BACKGROUND AND PURPOSE: Peroxisome proliferator-activated receptor (PPAR) agonists exert anti-albuminuric effects. However, the nephroprotective effects of these drugs remain to be fully understood. We have investigated whether gemfibrozil, GW0742 and pioglitazone protect human podocytes against nutrient deprivation (ND)-induced cell death and the role of mitochondrial biogenesis as a cytoprotective process. EXPERIMENTAL APPROACH: Immortalized human podocytes were pre-treated with the PPAR agonists and exposed to ND (5 h) under normoxia, hypoxia or in the presence of pyruvate. Cell death was measured at the end of the ND and of the recovery phase (24 h). Mitochondrial mass, cytochrome c oxidase (COX) subunits 1 and 4 were measured as markers of mitochondrial cell content, while membrane potential as an index of mitochondrial function. PGC-1α, NRF1 and Tfam expression was studied, as crucial regulators of mitochondrial biogenesis. KEY RESULTS: Cell pre-treatment with gemfibrozil, GW0742, or pioglitazone significantly decreased the ND-induced cell loss, necrosis and apoptosis. These effects were attenuated by hypoxia and potentiated by pyruvate. Pre-treatment with these drugs significantly increased mitochondrial cell content, while it did not affect mitochondrial function. In all these experiments pioglitazone exerted significantly larger effects than gemfibrozil or GW0742. CONCLUSIONS AND IMPLICATIONS: Gemfibrozil, GW0742 and pioglitazone may exert direct protective effects on human podocytes. Mitochondrial biogenesis is a cell response to the PPAR agonists related to their cytoprotective activity. These results provide a mechanistic support to the clinical evidence indicating PPAR agonists as disease-modifying agents for glomerular diseases.
Authors: H M Wright; C B Clish; T Mikami; S Hauser; K Yanagi; R Hiramatsu; C N Serhan; B M Spiegelman Journal: J Biol Chem Date: 2000-01-21 Impact factor: 5.157
Authors: Per Sauerberg; Ingrid Pettersson; Lone Jeppesen; Paul S Bury; John P Mogensen; Karsten Wassermann; Christian L Brand; Jeppe Sturis; Helle F Wöldike; Jan Fleckner; Anne-Sofie T Andersen; Steen B Mortensen; L Anders Svensson; Hanne B Rasmussen; Søren V Lehmann; Zdenek Polivka; Karel Sindelar; Vladimira Panajotova; Lars Ynddal; Erik M Wulff Journal: J Med Chem Date: 2002-02-14 Impact factor: 7.446
Authors: Mark C Wagner; George Rhodes; Exing Wang; Vikas Pruthi; Ehtesham Arif; Moin A Saleem; Sarah E Wean; Puneet Garg; Rakesh Verma; Lawrence B Holzman; Vince Gattone; Bruce A Molitoris; Deepak Nihalani Journal: J Biol Chem Date: 2008-10-14 Impact factor: 5.157
Authors: David M Small; Washington Y Sanchez; Sandrine F Roy; Christudas Morais; Heddwen L Brooks; Jeff S Coombes; David W Johnson; Glenda C Gobe Journal: Am J Physiol Renal Physiol Date: 2018-01-10
Authors: Ehtesham Arif; Ashish K Solanki; Pankaj Srivastava; Bushra Rahman; Wayne R Fitzgibbon; Peifeng Deng; Milos N Budisavljevic; Catalin F Baicu; Michael R Zile; Judit Megyesi; Michael G Janech; Sang-Ho Kwon; Justin Collier; Rick G Schnellmann; Deepak Nihalani Journal: Kidney Int Date: 2019-05-06 Impact factor: 10.612
Authors: S Agrawal; M A Chanley; D Westbrook; X Nie; T Kitao; A J Guess; R Benndorf; G Hidalgo; W E Smoyer Journal: Sci Rep Date: 2016-05-04 Impact factor: 4.379